AllianceBernstein
RCUS icon

AllianceBernstein’s Arcus Biosciences RCUS Stock Holding History

AllianceBernstein’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.96M Sell
124,085
-9,013
-7% -$195K ﹤0.01% 1789
2025
Q4 		$3.17M Sell
133,098
-4,091
-3% -$83.5K ﹤0.01% 1756
2025
Q3 		$1.87M Buy
137,189
+15,750
+13% +$164K ﹤0.01% 2042
2025
Q2 		$989K Buy
121,439
+8,179
+7% +$69.9K ﹤0.01% 2294
2025
Q1 		$889K Buy
113,260
+40,750
+56% +$472K ﹤0.01% 2302
2024
Q4 		$1.08M Sell
72,510
-1,228,444
-94% -$20.1M ﹤0.01% 2298
2024
Q3 		$19.9M Buy
1,300,954
+40,172
+3% +$633K 0.01% 916
2024
Q2 		$19.2M Buy
1,260,782
+109,654
+10% +$1.77M 0.01% 902
2024
Q1 		$21.7M Sell
1,151,128
-34,816
-3% -$602K 0.01% 846
2023
Q4 		$22.7M Buy
1,185,944
+251,361
+27% +$4.02M 0.01% 837
2023
Q3 		$16.8M Sell
934,583
-105,848
-10% -$2.13M 0.01% 907
2023
Q2 		$21.1M Buy
1,040,431
+22,502
+2% +$428K 0.01% 840
2023
Q1 		$18.6M Buy
1,017,929
+132,798
+15% +$2.54M 0.01% 870
2022
Q4 		$18.3M Sell
885,131
-151,466
-15% -$4.17M 0.01% 863
2022
Q3 		$27.1M Sell
1,036,597
-91,901
-8% -$2.43M 0.01% 737
2022
Q2 		$28.6M Buy
1,128,498
+58,555
+5% +$1.43M 0.01% 745
2022
Q1 		$33.8M Buy
1,069,943
+1,025,643
+2,315% +$34.4M 0.01% 727
2021
Q4 		$1.79M Sell
44,300
-7,200
-14% -$279K ﹤0.01% 2203
2021
Q3 		$1.8M Hold
51,500
– – ﹤0.01% 2228
2021
Q2 		$1.41M Buy
51,500
+6,500
+14% +$186K ﹤0.01% 2376
2021
Q1 		$1.26M Buy
45,000
+1,100
+3% +$38.3K ﹤0.01% 2313
2020
Q4 		$1.14M Hold
43,900
– – ﹤0.01% 2240
2020
Q3 		$752K Sell
43,900
-6,600
-13% -$147K ﹤0.01% 2311
2020
Q2 		$1.25M Buy
50,500
+11,800
+30% +$318K ﹤0.01% 2097
2020
Q1 		$537K Buy
38,700
+8,100
+26% +$101K ﹤0.01% 2316
2019
Q4 		$309K Buy
30,600
+2,900
+10% +$24.4K ﹤0.01% 2765
2019
Q3 		$252K Sell
27,700
-600
-2% -$4.82K ﹤0.01% 2860
2019
Q2 		$225K Buy
28,300
+6,600
+30% +$66.1K ﹤0.01% 2927
2019
Q1 		$271K Buy
21,700
+10,900
+101% +$118K ﹤0.01% 2800
2018
Q4 		$116K Buy
+10,800
New +$126K ﹤0.01% 2983

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AllianceBernstein's RCUS Position: Q1 2026 in Review

AllianceBernstein reduced its Arcus Biosciences (RCUS) stake by 6.8% in Q1 2026, selling an estimated $195K and leaving 124,085 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1789.

AllianceBernstein first reported a position in RCUS in Q4 2018 and has held it in 30 quarters since. The position peaked at $33.8M in Q1 2022. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • AllianceBernstein held 124,085 shares of Arcus Biosciences worth $2.96M as of Q1 2026.
  • AllianceBernstein sold 9,013 Arcus Biosciences shares in Q1 2026, an estimated $195K.
  • Arcus Biosciences made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1789 holding.
  • AllianceBernstein first reported a position in Arcus Biosciences in Q4 2018 and has held it in 30 quarters since.
  • AllianceBernstein's Arcus Biosciences position peaked at $33.8M in Q1 2022.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.